Stay updated with breaking news from Refractory Lymphomas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma and Hodgkin’s lymphoma Robust STAT3...
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor... | June 14, 2023
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target...
Data shared today in abstracts from the International Conference on Malignant Lymphoma Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose... | June 10, 2023